PolarityTE announced results from a multi-center randomized controlled trial evaluating treatment of Venous Leg Ulcers (VLU) with its investigational product SkinTE® plus standard of care (SOC) vs SOC alone (NCT03881267).
In this year’s legislative session, two bills could be problematic for life sciences companies in Utah. HB60 prohibits employers from requiring proof of vaccination from employees or patrons. While it provides an exemption for federally regulated entities like hospitals, it does not provide an exemption for life sciences employees who interact with those institutions who […]
Life Sciences Day on Capitol Hill was held on February 16 filling the Capitol rotunda with 24 companies showcasing their innovations to lawmakers and collectively, reflecting the strength of Utah’s BioHive. Lt. Governor Deidre Henderson was on hand to personally visit with company representatives and learn about the important work they’re doing to advance healthcare. […]
First-of-its kind metal-alloy angioplasty scoring sheath effective in treatment of critical arterial stenosis
Researchers at ARUP Laboratories made significant contributions to the advancement of laboratory medicine in 2021 as coauthors of more than 150 peer-reviewed articles in academic journals, medical guideline updates, and book chapters. They also contributed more than 40 posters or presentations at national and international medical conferences. Links to each of the 2021 publications and […]
PolarityTE, Inc. announced the U.S. Patent and Trademark Office (USPTO) recently issued a Notice of Allowance for U.S. Application No. 17/326,734 filed on May 21, 2021.
ARUP’s commitment to creating a satisfying work environment for employees has earned it a spot on Forbes’ list of America’s Best Midsize Employers for 2022.
Appointment further expands leadership team to support aggressive commercialization of the company’s PressON™ fixation, Tranquil™ interbody, and pending technologies
FDA-Cleared REMI Platform to Begin Initial Commercialization to Hospitals for Use in Emergency Departments and Intensive Care Units Across the United States
Originally published by IONIQ Sciences Dear IONIQ Sciences Shareholders and Friends, Greetings from IONIQ Sciences where we continue to follow the science and invest in exceptional team members, advisors and consultants to help us modernize early-stage cancer detection. LUNG Cancer – we have submitted our application to the FDA!! We have formally submitted our De Novo application to […]
BioPharm Laboratories, another journal article from the Journal of Biological Chemistry cites the use of BioPharm’s High Purity Thrombin being used to cleave protein in their protein purification process.
SALT LAKE CITY, Feb. 3, 2022 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd (“CoSara,” or the “JV”), its joint venture for manufacturing and sales in India, has received clearance by the Central […]
Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced that it will be hosting a booth at the upcoming Life Sciences Day on the Hill on February 16, 2022, at the Utah State Capital Building. It is expected that the conference, […]
New Nelson Labs Mark offers transparency and confidence in product testing
Salt Lake City, UT, February 2, 2022 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”) announced today that it has filed a De Novo application with the U.S. Food and Drug Administration (the “FDA”) for its IONIQ ProLung Test™ used for lung cancer. Mr. Jared Bauer, IONIQ Sciences CEO, stated, “Today we submitted our De […]
Fluidx Medical Reports Initial Research on First-of-its-Kind Embolic Agent with Intermediate Radiopacity
Biomerics inaugurated its second plant in Costa Rica.
Fluidx Medical’s Novel Embolic Device Demonstrates Repeated Success in Treating Complex Tumors
Foldax Appoints Scott Huennekens to Board of Directors
PolarityTE, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for the evaluation of SkinTE for the treatment of chronic cutaneous ulcers.
Co-Diagnostics, Inc. announced that CoSara Diagnostics Pvt Ltd has received clearance by the Central Drugs Standard Control Organization (“CDSCO”) in India to manufacture and sell its SARAGENE™ Human Papillomavirus High-Risk (HPV-HR) Real-Time PCR test as an in vitro diagnostic (“IVD”)
New Peripheral Vascular Microcatheters Save Procedure Time and Advance Treatment Capabilities
Positive Study Results Published for KidneyIntelXTM in Monitoring Patient Response to New Drug Therapy
Premier Neurology Facility in Colorado Joins the CenExel Centers of Excellence
CenExel Clinical Research, Inc. announced the acquisition of California Neuroscience Research.
Nexus Spine announced key appointments to its leadership team that includes David Ivanko as Vice President of Quality Engineering and Manufacturing and Andrew Shepherd as Vice President of Marketing.
Seventh KidneyIntelX implementation partnership for Renalytix focused on underserved populations with high disease burden
To help fight the pandemic, the FDA has been issuing EUAs and exercising enforcement discretion for medical devices needed to diagnose, treat, or prevent COVID-19. Last month, the agency issued two draft guidances related to transition plans to regular compliance for COVID-19 related medical devices that fall under EUAs or Agency Enforcement Policies that have […]
PARK CITY, Utah and HERZLIYA, Israel, Jan. 6, 2022 /PRNewswire/ — BlueWind Medical™, Ltd., developer of the innovative RENOVA™ iStim implantable neuromodulation device for treatment of Overactive Bladder, today announced additions to its leadership team in preparation for commercialization of the RENOVA product line. The company has added Mike Ruger as Vice President of Sales, Sandra […]
National program establishes early care management, technology innovation and large health system engagement as a strategic priority for supporting the 34 million U.S. individuals living with diabetes
Series A Financing Funds Multiple Programs to Phase 1 and IND stage
Definitive merger agreements provide the Company with all existing and future assets, future product iterations, and intellectual property rights of the platform, creating a fully integrated product line and streamlining commercialization
